Infection regulates pro-resolving mediators that lower antibiotic requirements (original) (raw)

Nature volume 484, pages 524–528 (2012)Cite this article

Subjects

Abstract

Underlying mechanisms for how bacterial infections contribute to active resolution of acute inflammation are unknown1,2,3,4. Here, we performed exudate leukocyte trafficking and mediator-metabololipidomics of murine peritoneal Escherichia coli infections with temporal identification of pro-inflammatory (prostaglandins and leukotrienes) and specialized pro-resolving mediators (SPMs). In self-resolving E. coli exudates (105 colony forming units, c.f.u.), the dominant SPMs identified were resolvin (Rv) D5 and protectin D1 (PD1), which at 12 h were at significantly greater levels than in exudates from higher titre E. coli (107 c.f.u.)-challenged mice. Germ-free mice had endogenous RvD1 and PD1 levels higher than in conventional mice. RvD1 and RvD5 (nanograms per mouse) each reduced bacterial titres in blood and exudates, _E. coli_-induced hypothermia and increased survival, demonstrating the first actions of RvD5. With human polymorphonuclear neutrophils and macrophages, RvD1, RvD5 and PD1 each directly enhanced phagocytosis of E. coli, and RvD5 counter-regulated a panel of pro-inflammatory genes, including NF-κB and TNF-α. RvD5 activated the RvD1 receptor, GPR32, to enhance phagocytosis. With self-limited E. coli infections, RvD1 and the antibiotic ciprofloxacin accelerated resolution, each shortening resolution intervals (_R_i). Host-directed RvD1 actions enhanced ciprofloxacin’s therapeutic actions. In 107 c.f.u. E. coli infections, SPMs (RvD1, RvD5, PD1) together with ciprofloxacin also heightened host antimicrobial responses. In skin infections, SPMs enhanced vancomycin clearance of Staphylococcus aureus. These results demonstrate that specific SPMs are temporally and differentially regulated during infections and that they are anti-phlogistic, enhance containment and lower antibiotic requirements for bacterial clearance.

This is a preview of subscription content, access via your institution

Access options

Subscribe to this journal

Receive 51 print issues and online access

$199.00 per year

only $3.90 per issue

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Additional access options:

Similar content being viewed by others

References

  1. Houck, J. C., ed. Chemical Messengers of the Inflammatory Process (Elsevier/North-Holland Biomedical Press, 1979)
    Google Scholar
  2. Mantovani, A., Cassatella, M. A., Costantini, C. & Jaillon, S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nature Rev. Immunol. 11, 519–531 (2011)
    Article CAS Google Scholar
  3. Medzhitov, R. Inflammation 2010: new adventures of an old flame. Cell 140, 771–776 (2010)
    Article CAS Google Scholar
  4. Serhan, C. N. Resolution phases of inflammation: novel endogenous anti-inflammatory and pro-resolving lipid mediators and pathways. Annu. Rev. Immunol. 25, 101–137 (2007)
    Article CAS Google Scholar
  5. Stables, M. J. & Gilroy, D. W. Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res. 50, 35–51 (2011)
    Article CAS Google Scholar
  6. Henneke, P. & Golenbock, D. T. Phagocytosis, innate immunity, and host-pathogen specificity. J. Exp. Med. 199, 1–4 (2004)
    Article CAS Google Scholar
  7. Rossi, A. G. et al. Cyclin-dependent kinase inhibitors enhance the resolution of inflammation by promoting inflammatory cell apoptosis. Nature Med. 12, 1056–1064 (2006)
    Article CAS Google Scholar
  8. Dinarello, C. A. Anti-inflammatory agents: present and future. Cell 140, 935–950 (2010)
    Article CAS Google Scholar
  9. Navarro-Xavier, R. A. et al. A new strategy for the identification of novel molecules with targeted proresolution of inflammation properties. J. Immunol. 184, 1516–1525 (2010)
    Article CAS Google Scholar
  10. Schif-Zuck, S. et al. Satiated-efferocytosis generates pro-resolving CD11blow macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366–379 (2011)
    Article CAS Google Scholar
  11. De Caterina, R. n−3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364, 2439–2450 (2011)
    Article CAS Google Scholar
  12. Morris, T. et al. Effects of low-dose aspirin on acute inflammatory responses in humans. J. Immunol. 183, 2089–2096 (2009)
    Article CAS Google Scholar
  13. Oh, S. F., Pillai, P. S., Recchiuti, A., Yang, R. & Serhan, C. N. Pro-resolving actions and stereoselective biosynthesis of 18_S_ E-series resolvins in human leukocytes and murine inflammation. J. Clin. Invest. 121, 569–581 (2011)
    Article CAS Google Scholar
  14. Spite, M. et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 461, 1287–1291 (2009)
    Article ADS CAS Google Scholar
  15. Mead, P. S. et al. Food-related illness and death in the United States. Emerg. Infect. Dis. 5, 607–625 (1999)
    Article CAS Google Scholar
  16. Klingensmith, M. E. & Soybel, D. I. in The Physiological Basis of Modern Surgical Care ( Miller, T. A. & Rowlands, B. J. eds) 478–490 (Mosby Year Book, 1998)
    Google Scholar
  17. Xu, Y. N., Zhang, Z., Ma, P. & Zhang, S. H. Adenovirus-delivered angiopoietin 1 accelerates the resolution of inflammation of acute endotoxic lung injury in mice. Anesth. Analg. 112, 1403–1410 (2011)
    Article Google Scholar
  18. Serhan, C. N. et al. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter pro-inflammation signals. J. Exp. Med. 196, 1025–1037 (2002)
    Article CAS Google Scholar
  19. Bäckhed, F., Manchester, J. K., Semenkovich, C. F. & Gordon, J. I. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc. Natl Acad. Sci. USA 104, 979–984 (2007)
    Article ADS Google Scholar
  20. Krishnamoorthy, S. et al. Resolvin D1 binds human phagocytes with evidence for pro-resolving receptors. Proc. Natl Acad. Sci. USA 107, 1660–1665 (2010)
    Article ADS CAS Google Scholar
  21. Grkovich, A., Johnson, C. A., Buczynski, M. W. & Dennis, E. A. Lipopolysaccharide-induced cyclooxygenase-2 expression in human U937 macrophages is phosphatidic acid phosphohydrolase-1-dependent. J. Biol. Chem. 281, 32978–32987 (2006)
    Article CAS Google Scholar
  22. Jin, S. L., Lan, L., Zoudilova, M. & Conti, M. Specific role of phosphodiesterase 4B in lipopolysaccharide-induced signaling in mouse macrophages. J. Immunol. 175, 1523–1531 (2005)
    Article CAS Google Scholar
  23. Link, A., Selejan, S., Maack, C., Lenz, M. & Böhm, M. Phosphodiesterase 4 inhibition but not beta-adrenergic stimulation suppresses tumor necrosis factor-alpha release in peripheral blood mononuclear cells in septic shock. Crit. Care 12, R159 (2008)
    Article Google Scholar
  24. Stables, M. J. et al. Priming innate immune responses to infection by cyclooxygenase inhibition kills antibiotic-susceptible and -resistant bacteria. Blood 116, 2950–2959 (2010)
    Article CAS Google Scholar
  25. World Health Organization. Antibiotics Resistance, Factsheet No. 194 http://www.who.int/mediacentre/factsheets/fs194/en/ (February 2011)
  26. Seki, H. et al. The anti-inflammatory and proresolving mediator resolvin E1 protects mice from bacterial pneumonia and acute lung injury. J. Immunol. 184, 836–843 (2010)
    Article CAS Google Scholar
  27. El Kebir, D. et al. 15-epi-lipoxin A4 inhibits myeloperoxidase signaling and enhances resolution of acute lung injury. Am. J. Respir. Crit. Care Med. 180, 311–319 (2009)
    Article CAS Google Scholar
  28. Prescott, D. & McKay, D. M. Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G487–G497 (2011)
    Article CAS Google Scholar
  29. Yang, R., Chiang, N., Oh, S. F. & Serhan, C. N. Metabolomics-lipidomics of eicosanoids and docosanoids generated by phagocytes. Curr. Protoc. Immunol. 95, 14.26.11–14.26.26 (2011)
    Article Google Scholar
  30. Winyard, P. G., Willoughby, D. A., eds. Inflammation Protocols (Humana, 2003)
    Book Google Scholar

Download references

Acknowledgements

The authors thank M. Small for assistance with manuscript preparation, J. Lederer for cytokine measurements, J. Dalli for discussions, and N. Petasis for preparation of deuterium-labelled RvD1. This work was supported in part by NIH grants P01GM095467 and R01GM38765 (C.N.S.).

Author information

Authors and Affiliations

  1. Department of Anesthesiology, Center for Experimental Therapeutics and Reperfusion Injury, Perioperative and Pain Medicine, Harvard Institutes of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, 02115, Massachusetts, USA
    Nan Chiang, Gabrielle Fredman, Sungwhan F. Oh, Thad Vickery, Birgitta A. Schmidt & Charles N. Serhan
  2. Sahlgrenska Center for Cardiovascular and Metabolic Research/Wallenberg Laboratory, University of Gothenburg, SE-413 45 Gothenburg, Sweden ,
    Fredrik Bäckhed

Authors

  1. Nan Chiang
    You can also search for this author inPubMed Google Scholar
  2. Gabrielle Fredman
    You can also search for this author inPubMed Google Scholar
  3. Fredrik Bäckhed
    You can also search for this author inPubMed Google Scholar
  4. Sungwhan F. Oh
    You can also search for this author inPubMed Google Scholar
  5. Thad Vickery
    You can also search for this author inPubMed Google Scholar
  6. Birgitta A. Schmidt
    You can also search for this author inPubMed Google Scholar
  7. Charles N. Serhan
    You can also search for this author inPubMed Google Scholar

Contributions

N.C., G.F. and S.F.O. contributed to experimental design, carried out experiments and data analyses. T.V. and S.F.O. performed metabololipidomics and lipid mediator analyses. F.B. carried out experiments with germ-free mice and contributed to manuscript composition. B.A.S. carried out dermatopathology. All authors contributed to manuscript presentation and figure preparation. N.C. and C.N.S. carried out overall experimental design and C.N.S. conceived of the overall research plan.

Corresponding author

Correspondence toCharles N. Serhan.

Ethics declarations

Competing interests

C.N.S. is an inventor on patents (resolvins) assigned to BWH and licensed to Resolvyx Pharmaceuticals. C.N.S. is a scientific founder of Resolvyx Pharmaceuticals and owns equity in the company. C.N.S.’ interests were reviewed and are managed by the Brigham and Women’s Hospital and Partners HealthCare in accordance with their conflict of interest policies.

Supplementary information

Supplementary Information

This file contains Supplementary Tables 1-3, Supplementary Figures 1-11 and an additional reference. (PDF 24452 kb)

PowerPoint slides

Rights and permissions

About this article

Cite this article

Chiang, N., Fredman, G., Bäckhed, F. et al. Infection regulates pro-resolving mediators that lower antibiotic requirements.Nature 484, 524–528 (2012). https://doi.org/10.1038/nature11042

Download citation

This article is cited by

Editorial Summary

Helper molecules for antibiotics

Bacterial infections can result in the generation of infection-resolving anti-inflammatory lipid derivatives. This paper reports the use of a murine Escherichia coli peritonitis model relevant to human infections to identify specialized host-produced pro-resolving mediators (SPMs) termed resolvin D5 and protectin D1, which may be directly involved in resolving infections. The administration of these two mediators improves infection-related signs, increases clearance of infection-causing bacteria and increases survival. When administered with antibiotics, resolvin D5 and protectin D1 acted together to further reduce the duration and severity of infection. The SPMs also enhanced antibiotic clearance of Staphylococcus aureus murine skin infections. The spread of antibiotic resistance is a major concern, so the prospect that therapeutic use of host-derived molecules might help to limit antibiotic dose rates is of potential clinical importance.